RecruitingNCT06215508

Geriatric Assessment and Technology Evaluation in Prostate Cancer

Prostate Cancer Geriatric Assessment and Technology Evaluation (ProsGATE) Study

Sponsor

University of Chicago

Enrollment

120 participants

Start Date

Apr 1, 2026

Study Type

OBSERVATIONAL

Conditions

Prostate Cancer Prostate Cancer Metastatic

Summary

By doing this study, doctors hope to learn more about factors that contribute to frailty (a condition where older adults feel weak, get tired easily, and struggle more with everyday activities) and serious side effects among men over the age of 65 who will receive androgen deprivation therapy (also called "hormone therapy") for prostate cancer that has spread to other parts of their body. Participation in this research will last about 5 years. For the first year, participants will have 5 study visits where they have give blood samples, answer survey questions, and use a wearable device. After study visits are complete, there is a 4-year follow-up period. Research team will check regular doctor visits and look at participants' medical records.

Eligibility

Sex: MALEMin Age: 18 Minutes

Plain Language Summary

Simplified for easier understanding

This trial is studying how well standard geriatric assessment tools — structured evaluations of physical function, cognition, and social support in older adults — work in predicting outcomes for older men with metastatic prostate cancer starting intensive hormone therapy. The goal is to personalize care for elderly patients by identifying who may struggle with treatment side effects. **You may be eligible if...** - You are 65 or older - You have prostate cancer that has spread to other parts of the body (metastatic) - You are about to start intensified hormone therapy (combined androgen deprivation therapy and an androgen receptor signaling inhibitor) - Your cancer has been confirmed by biopsy - You are able and willing to provide informed consent **You may NOT be eligible if...** - You have received hormone therapy in the past 12 months (except within the past 12 weeks) - You have already had chemotherapy for metastatic prostate cancer - You have had surgical removal of the testicles more than 12 weeks before your metastatic diagnosis - You have uncontrolled serious medical conditions at the time of enrollment Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.